Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.62)
# 279
Out of 4,433 analysts
36
Total ratings
61.22%
Success rate
22.45%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Initiates: Outperform | $85 | $52.79 | +61.02% | 1 | May 14, 2024 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $50 | $31.04 | +61.08% | 1 | May 14, 2024 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $175 | $141.91 | +23.32% | 1 | May 14, 2024 | |
| MRNA Moderna | Initiates: In-Line | $120 | $132.68 | -9.56% | 2 | May 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $967.98 | +18.80% | 3 | May 14, 2024 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $113 | $76.97 | +46.81% | 3 | May 14, 2024 | |
| BNTX BioNTech SE | Initiates: In-Line | $100 | $92.98 | +7.55% | 2 | May 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $84 → $88 | $42.61 | +106.52% | 4 | Feb 27, 2024 | |
| CERE Cerevel Therapeutics Holdings | Initiates: Overweight | $50 | $42.35 | +18.06% | 1 | Jan 5, 2022 | |
| BIIB Biogen | Maintains: Neutral | $324 → $276 | $230.04 | +19.98% | 2 | Dec 21, 2021 | |
| SANA Sana Biotechnology | Initiates: Neutral | n/a | $8.55 | - | 1 | Mar 1, 2021 | |
| BLUE bluebird bio | Downgrades: Neutral | n/a | $1.05 | - | 1 | Feb 17, 2021 | |
| INCY Incyte | Downgrades: Neutral | n/a | $56.86 | - | 2 | May 6, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $67.86 | - | 1 | May 1, 2020 | |
| ALKS Alkermes | Downgrades: Neutral | n/a | $24.46 | - | 2 | Feb 14, 2020 | |
| PBYI Puma Biotechnology | Maintains: Underweight | n/a | $4.41 | - | 4 | Nov 2, 2018 | |
| AMGN Amgen | Maintains: Neutral | n/a | $314.72 | - | 2 | Jul 27, 2018 | |
| LXRX Lexicon Pharmaceuticals | Maintains: Underweight | n/a | $1.84 | - | 1 | Feb 14, 2018 | |
| DVAX Dynavax Technologies | Maintains: Neutral | n/a | $11.28 | - | 1 | Feb 14, 2018 | |
| LIFE aTyr Pharma | Downgrades: Underweight | n/a | $1.93 | - | 1 | Feb 14, 2018 |
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $52.79
Upside: +61.02%
BridgeBio Pharma
May 14, 2024
Initiates: Outperform
Price Target: $50
Current: $31.04
Upside: +61.08%
Neurocrine Biosciences
May 14, 2024
Initiates: Outperform
Price Target: $175
Current: $141.91
Upside: +23.32%
Moderna
May 14, 2024
Initiates: In-Line
Price Target: $120
Current: $132.68
Upside: -9.56%
Regeneron Pharmaceuticals
May 14, 2024
Initiates: Outperform
Price Target: $1,150
Current: $967.98
Upside: +18.80%
BioMarin Pharmaceutical
May 14, 2024
Initiates: Outperform
Price Target: $113
Current: $76.97
Upside: +46.81%
BioNTech SE
May 14, 2024
Initiates: In-Line
Price Target: $100
Current: $92.98
Upside: +7.55%
Ultragenyx Pharmaceutical
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $42.61
Upside: +106.52%
Cerevel Therapeutics Holdings
Jan 5, 2022
Initiates: Overweight
Price Target: $50
Current: $42.35
Upside: +18.06%
Biogen
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $230.04
Upside: +19.98%
Sana Biotechnology
Mar 1, 2021
Initiates: Neutral
Price Target: n/a
Current: $8.55
Upside: -
bluebird bio
Feb 17, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.05
Upside: -
Incyte
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $56.86
Upside: -
Gilead Sciences
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $67.86
Upside: -
Alkermes
Feb 14, 2020
Downgrades: Neutral
Price Target: n/a
Current: $24.46
Upside: -
Puma Biotechnology
Nov 2, 2018
Maintains: Underweight
Price Target: n/a
Current: $4.41
Upside: -
Amgen
Jul 27, 2018
Maintains: Neutral
Price Target: n/a
Current: $314.72
Upside: -
Lexicon Pharmaceuticals
Feb 14, 2018
Maintains: Underweight
Price Target: n/a
Current: $1.84
Upside: -
Dynavax Technologies
Feb 14, 2018
Maintains: Neutral
Price Target: n/a
Current: $11.28
Upside: -
aTyr Pharma
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $1.93
Upside: -